Pituitary & hypothalamus

Transsphenoidal Surgery for Pituitary Neuroendocrine Tumours (PiTNETs) in a Tertiary Hospital: Are There Differences Between Young and Elderly Patients?

Clin Endocrinol (Oxf)Published Retrospective cohort study

Authors' conclusion

With experienced surgical and endocrinological care, transsphenoidal surgery for elderly patients with PiTNET is effective and safe.

Study context

Population
Adults undergoing transsphenoidal surgery for PiTNET in a tertiary hospital, 2018–2023
Participants
124 adults
Exposure
Elderly vs younger patients undergoing transsphenoidal surgery
  • Elderlyn = 32
Outcome
Hormonal excess
Methodological detailsobservational, single-centre
  • Observational
  • Single-centre

Main finding

As reported in the abstract

P < 0.001

Observational data: associations, not effects.

Further findings

Hypopituitarism · higher with Elderly

P < 0.001

Macroadenomas · higher with Elderly

P = 0.002

Ki67 · lower with Elderly

P = 0.045

Median

OutcomeElderlyYoungerP value
Number of affected axesGreater with Elderly31P < 0.001
ACTH excess
P = 0.003

ACTH excess

Only the rate of ACTH excess differed between groups

Most common surgical indication

Elderly: visual impairment
31.3%
Younger: functionality
42.4%, p = 0.012

Knosp grade

No differences in Knosp grade

Tumour resection rate, visual improvement, hormonal status · 6-12 months

No differences in tumour resection rate, visual improvement or hormonal status

Safety

Immediate postsurgical complications and hospital stay · immediate postsurgical period

No differences in surgical or hormonal complications or hospital stay

Original publication

Transsphenoidal Surgery for Pituitary Neuroendocrine Tumours (PiTNETs) in a Tertiary Hospital: Are There Differences Between Young and Elderly Patients? Clin Endocrinol (Oxf). Published 24 March 2025. doi:10.1111/cen.15242

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.